Latest news

Adalvo announces the partial completion of an acquisition of a pharmaceutical portfolio from Sandoz, comprising four well-established branded products, across more than 60+ markets. With the partial completion of this acquisition, Adalvo...

A Phase III clinical study sponsored by Adalvo has been published in the Journal of Pain Practice, demonstrating that the once-daily prolonged-release (PR) formulation of Pregabalin is as effective and...

Adalvo, in collaboration with its partners, has successfully launched Dapagliflozin film-coated tablets in the UK, marking the first European launch of this blockbuster diabetes and cardiovascular treatment. As an early entry market, the UK...

Adalvo is on target to launch Teduglutide in Europe in Q1 2026, following the anticipated closure of the DCP towards the end of 2025. In parallel with the EU filing,...

On World Lung Cancer Day, Adalvo highlights its commitment to improving access to high-quality, life-extending treatments for patients affected by lung cancer, the leading cause of cancer-related deaths worldwide.  With millions...

Adalvo confirms the submission of DCP applications for both Tafamidis Meglumine 20mg and Tafamidis 61mg soft gel capsules, marking a key milestone in its strategy to expand access to treatment...

Adalvo announces the successful launch of Azelastine/Fluticasone nasal spray across several key European markets, strengthening its position in the allergy and respiratory segment. Based on the reference brand Dymista®, the product is indicated for the treatment of seasonal...

Malta, 18th July 2025 - EQT, a leading global investment firm with a strong track record of owning and developing healthcare companies around the world, today announced that it has...

Adalvo will submit the DCP application for Cladribine Tablets 10mg in August 2025, following the expiry of data exclusivity in key EU markets.  Cladribine is indicated for the treatment of relapsing...

Adalvo is progressing its Binimetinib program, targeting a Day-1 launch opportunity upon expiry of the IP Rights in major regulated markets through a clearly defined IP strategy. The program is...

Adalvo has submitted the DCP application for Fidaxomicin 200mg tablets, advancing its strategy to expand access to complex anti-infective therapies across key regulated markets.  This follows a recent ANDA filing...

Adalvo is preparing to submit DCP applications for both Tafamidis Meglumine 20mg and Tafamidis Base 61mg soft gel capsules in July 2025, strengthening its strategic commitment to expanding access to treatments...

Adalvo announces a positive outcome from the pilot bioequivalence (BE) study for its Lenvatinib 2mg/ml Oral Solution (OS), a patient-friendly formulation designed to expand access to Lenvatinib therapy.  This result marks significant progress toward...

Adalvo continues to progress its Apalutamide development program, with the regulatory dossier expected to be completed by the end of 2025, paving the way for early market access in several regions, including...

Adalvo is ready to submit the DCP application for Dapagliflozin + Metformin IR fixed-dose combination tablet in August 2025, expanding its metabolic portfolio with a clinically established treatment for type...

Adalvo announces plans to submit the DCP for Cariprazine Capsules in October 2025, expanding its CNS pipeline with a targeted product addressing unmet needs in schizophrenia treatment.  Based on the reference...

Adalvo is ready to submit the DCP application for Dimethyl Fumarate gastro-resistant tablets (30mg and 120mg), targeting the treatment of moderate to severe plaque psoriasis in adult patients.   With the...